drugset / Trial / NCT05942625

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects

NCT05942625

Phase 1 Recruiting 84 enrolled Hansoh BioMedical R&D Company
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of this first in human study is to evaluate the safety, tolerability, pharmacokinetics (PK),and pharmacodynamics (PD) of HS-10390 in healthy subjects.

Timeline

Start
2023-05-23
Primary completion
2024-06-30
Completion
2024-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HS-10390 Unknown Oral